The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hep C Medicine Management: Anxiety

Back to News Homepage

Next

Hep C Lifestyle Guide: Good and Bad Thanksgiving Meal Sides

ABT-450 Shows Promising Results for Hepatitis C Patients

November 6, 2013

Print this page

A Phase 2b trial of ABT-450 (a once-a-day, all-oral drug regimen) revealed an average sustained virologic response of 95 percent in newly-diagnosed patients.

Trial data analysis shows Enanta’s hepatitis C drug is effective

November 4, 2013

By Don Seiffert
BioFlash Editor- Boston Business Journal

Enanta Pharmaceuticals’ partner on a potential drug for hepatitis C presented some promising early results from a mid-stage study of the drug over the weekend.

The Watertown biotech has developed a lead drug, a so-called protease inhibitor named ABT-450, which is part of a hepatitis C drug being tested by Abbott Laboratories. The once-a-day, all-oral drug regimen is notable in that it doesn’t contain interferon, which has been used in previous treatments for hepatitis C but causes flu-like side effects. Several companies are in the late stages of developing interferon-free drugs to treat the infectious liver disease that affects up to 200 million people worldwide. Abbott gave results of a Phase 2b trial of the drug on Sunday at the annual meeting of the American Association for the Study of Liver Diseases in Washington.

Continue reading this entire article:
http://www.bizjournals.com/boston/blog/bioflash/2013/11/trial-data-so-far-shows-enantas.html

14 Comments
Share
Share

Previous

Hep C Medicine Management: Anxiety

Back to News Homepage

Next

Hep C Lifestyle Guide: Good and Bad Thanksgiving Meal Sides

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.